Soluble cytokine receptors in biological therapy (Q34779777)

4 August 2017

1 reference

title

Soluble cytokine receptors in biological therapy (English)

1 reference

4 August 2017

author name string

Rafael Fernandez-Botran

series ordinal

1

1 reference

4 August 2017

Fabian A Crespo

series ordinal

2

1 reference

4 August 2017

Xichun Sun

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Expert Opinion on Biological Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

6

1 reference

4 August 2017

page(s)

585-605

1 reference

Soluble cytokine receptors: novel immunotherapeutic agents

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The potential biological and clinical significance of the soluble tumor necrosis factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Signaling through the hematopoietic cytokine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The soluble interleukin 6 receptor: mechanisms of production and implications in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Cytokines and anticytokines in the pathogenesis of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Soluble cytokine receptors: basic immunology and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

T-cell subsets (Th1 versus Th2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The soluble interleukin-2 receptor: biology, function, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Why immunomodulatory therapies have not worked in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Impact of immunomodulating therapy on morbidity in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The role of cytokines in the neuropathology of stroke and neurotrauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Neuroprotective effects of TNF binding protein in focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The locus of tumor necrosis factor-alpha action in lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Effect of inhibitor of tumor necrosis factor-alpha on experimental otitis media with effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Etanercept reduces hyperalgesia in experimental painful neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Hereditary periodic fever syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Infliximab: a review of its use in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Cytokine-directed therapies for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Interleukin 1 signaling occurs exclusively via the type I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Antagonism of the IL-6 cytokine subfamily--a potential strategy for more effective therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Sympathetic neurons can produce and respond to interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

A major binding protein for leukemia inhibitory factor in normal mouse serum: identification as a soluble form of the cellular receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The human hematopoietic colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

The IFN gamma receptor: a paradigm for cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

Identification and Characterization of Two Distinct Truncated Forms of gp130 and a Soluble Form of Leukemia Inhibitory Factor Receptor α-Chain in Normal Human Urine and Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.6.585

21 January 2018

Identifiers

DOI

10.1517/14712598.2.6.585

1 reference

4 August 2017

1 reference